There are long‐term beneficial responses in NSCLC patients after receiving ICI drugs that target on the PD‐L1;10, 11 however, only a fewer percentage of sufferers have a response to this immunotherapy.12 This evidence concerns the gene CD274 and non-small cell lung carcinoma.